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Summary
The World Health Organization (WHO) assigns high pri-
ority to the prevention of non-communicable age-related
diseases such as heart disease, cancer, diabetes, stroke and
chronic lower respiratory diseases. They are now the lead-
ing causes of death, in both industrialised and developing
countries, mostly due to increased life expectancy and urb-
anisation with associated changes in lifestyle and environ-
ment. Tobacco smoking, physical inactivity and resulting
obesity are established risk factors for many chronic dis-
eases. Yet, the aetiology of age-related diseases is complex
and varies between individuals. This often makes it diffi-
cult to identify causal risk factors, especially if their re-
lative effects are weak. For example, the associations of
both obesity and air pollution with several age-related dis-
eases remain poorly understood with regard to causality
and biological mechanisms. Exposure to both, excess body
fat and particulate matter, is accompanied by systemic low-
grade inflammation as well as alterations in insulin/insulin-
like growth factor signalling and cell cycle control. These
mechanisms have also been associated in animal and some
human studies with longevity and ageing in more general
terms. In this paper, it is therefore hypothesised that they
may, at least in part, be responsible for the adverse health
effects of obesity and air pollution. It is argued that molecu-
lar and genetic epidemiology now offer novel instruments
to improve the understanding of these pathophysiological
pathways and their link to disease aetiology. Understanding
the causality of exposure disease associations and differen-
ces in susceptibilities to environment and lifestyle is an im-
portant aspect for effective prevention.
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Non-communicable age-related
diseases – a global challenge
The World Health Organization (WHO) assigns high pri-
ority to the prevention of chronic diseases in all parts of
the world [1]. Non-communicable age-related diseases
(NCDs) such as heart disease, cancer, stroke and chronic
lower respiratory diseases are now the leading causes of
death, in both industrialised and developing countries.
From the perspective of society, the increase in average life
expectancy, living in an urban environment and the west-
ernisation of lifestyle are the most important risk factors
for the global increases in NCD morbidity and mortality.
At the centre of strategies to improve the health of people
must be behavioural and environmental risks, as these can
be modified [2]. Yet, the aetiology of NCDs is complex
and varies between individuals. This often makes it diffi-
cult to identify causal risk factors, especially if their relat-
ive effects are weak (i.e. air pollution, passive smoking).
The expectations for molecular epidemiology and genetics
in chronic disease epidemiology are to improve the under-
standing of causality in exposure-disease associations as
well as of disease susceptibilities. In addition, they will
help elucidate the biological mechanisms underlying dis-
eases, as well as the adverse health effects of exogenous
risk factors [3–5].
Age-related diseases share risk
factors: do they share
pathophysiological pathways?
No longer can each chronic illness be considered in isola-
tion. Awareness is increasing that they share common, usu-
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ally related risk factors, and that integrated strategies can
be effective for many different conditions [6].
Understanding common risk and disease patterns, as
well as their causal links and underlying biological mech-
anisms, is important for public health. It helps target pre-
vention to causal aspects of lifestyle and environment that
are generally unhealthy. This strengthens strategies to in-
crease the amount of life spent in good health [7–9]. The
hypothesis of shared aetiologies between diseases is sup-
ported by evidence, that the presence of one chronic dis-
ease in a person is often associated with an increased risk
for developing additional health conditions [10–11]. Res-
ults from genetics and genomics also suggest that diseases
are not as independent of each other as was believed in the
past [12–13]. A paradigm shift in disease categorisation is
taking place. Efforts are under way to systematically link
all genetic disorders (the human "disease phenome”) with
the complete list of disease genes (the "disease genome”)
[12–13]. They offer the opportunity to identify general pat-
terns underlying human health and disease. Unfortunately,
these efforts to identify the "diseasome” of all known dis-
order and gene associations largely ignore the social and
physical environment in which humans live and function
[12–13]. This is a severe limitation, as only modifiable risk
factors can be the target of prevention.
Systemic inflammation, insulin
resistance, and alterations in cell
cycle control: public health-relevant
disease mechanisms?
Different biological mechanisms and genes have been as-
sociated with more than one disease or risk factor. This
paper focuses on the hypothesis that systemic inflamma-
tion, insulin resistance and alterations in cell cycle may po-
tentially belong to the many public health-relevant patho-
physiologies. The reasoning is based on two globally im-
portant risk factors with broad adverse health effects,
namely obesity and air pollution. Both have important links
to systemic inflammation, oxidative stress and insulin res-
istance. However, whether these mechanisms are only bio-
markers of exposure or active players in disease causation
is still debated in several circumstances. Resolving the
question of causality will have important implications for
prevention.
How obesity may shorten life
According to observational studies, obesity is a major de-
terminant of premature mortality and a risk factor for the
most significant causes of death such as type II diabetes,
cardiovascular disease and various types of cancer [14–15].
Although in some cases, being overweight is also known
to protect against age-related health problems such as bone
fractures and osteoporosis [16]. A large retrospective study
on the long term impact of gastric bypass surgery showed
that weight loss was associa-
ted with a decrease in overall mortality as well as in mortal-
ity due to diabetes, heart disease and cancer, whereas mor-
tality due to other causes such as accidents and suicide was
increased in the treatment group [17–18]. Despite the broad
evidence on the diverse health effects of obesity, many
open questions remain regarding its association with chron-
ic diseases. The causality of the association with specific
diseases, such as some types of cancer or asthma, is still
debated. From a public health perspective, it is important
to weigh the adverse overweight effects against some of its
protective effects. The relevance of different obesity mark-
ers is the focus of ongoing research. Finally, the patho-
physiological mechanisms underlying the health effects of
obesity remain to be fully elucidated [19]. Systemic low-
grade inflammation and insulin resistance are two related
mechanisms hypothesised to play a role in at least part of
the obesity-disease associations. They are also present in
many obesity-associated chronic diseases, including type
2 diabetes, hypertension, cardiovascular disease as well as
some types of cancer [20–21], but the causality of all these
interrelationships is often unclear [22].
Insulin/IGF-1 signalling: association
with obesity, caloric restriction and
longevity
Obesity, especially visceral adiposity, is associa-
ted with insulin resistance. In insulin resistance, serum
levels of insulin and insulin-like growth factors are elev-
ated and insulin/IGF-1 signalling is altered. Insulin res-
istance plays a physiological role in the pre- and post-
natal period for growth stimulation. However, after pu-
berty, IGF-1 serum levels decline. Persistent insulin res-
istance in late adolescence and adulthood is a risk factor
of chronic diseases [21, 23] and may well be one of the
key pathophysiological mechanisms mediating the adverse
health effects of a western lifestyle and environment.
The impact of long-term caloric restriction on lifespan
and decreased incidence of both neoplastic and non-neo-
plastic lesions in mammals has been attributed, in part,
to alterations in insulin/IGF-1 signalling [24]. Clearly, the
mechanisms underlying the impact of caloric restriction are
complex and not fully understood. However, it has been
found that circulating levels of anabolic hormones and hor-
mones that regulate thermogenesis and cellular metabolism
are lower. Animals with restricted energy intake cope bet-
ter with a broad array of acute stressors. They exhibit en-
hanced DNA repair, probably through an adaptation called
hormesis. However, alterations of insulin/IGF-1 signalling
and associated systemic inflammation are, potentially, also
very important in mediating the effect of caloric restriction
[20], as reduced IGF-1 signalling promotes longevity in
several animal models. This effect has been attributed, in
part, to a decreased occurrence of several age-related dis-
eases.
Humans who live to an old age are less likely to exhibit
insulin resistance. Metabolic characteristics promoted by
caloric restriction in humans living to very old ages include
low circulating levels of fasting plasma glucose, insulin,
free insulin and IGF-1 levels. Long-term calorie restriction
without malnutrition is also associated with decreased
levels of oxidative markers in blood and urine and protects
against systemic inflammation [25–26]. Yet, in general, the
effects of caloric restriction in humans are inconsistent and
are likely to be complex [20, 27–28]. The impact of long-
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term caloric restriction accompanied by adequate nutrient
supply on the burden of chronic diseases in humans re-
mains to be proven [20] and must be carefully weighed
against some of the beneficial health effects of being over-
weight, especially at higher age.
Systemic low-grade inflammation: its
links to obesity, insulin/IGF-1
signalling and cell cycle control
Chronic inflammation and reactive oxygen species damage
molecules, tissues and organs, and are a key feature of
ageing and many chronic diseases [25–26]. Many markers
associated with biological ageing are related to chronic
inflammation, such as serum levels of IL-6, IL-1beta or
TNF-α [25–26]. Elderly subjects exhibit higher circulating
levels of pro-inflammatory molecules in their circulation.
Blood concentrations of these pro-inflammatory substances
during childhood and adolescence are predictive of mor-
bidity and mortality in adulthood. It has been hypothesised
that systemic subclinical inflammation may, in part, reflect
ageing processes of the immune system. Chronic or repet-
itive infections and lifelong exposures to antigens decrease
the efficiency of immune cells in fighting invaders over
time. Possibly in reaction to this decreased effectiveness,
apoptosis of immune cells, particularly neutrophils, dimin-
ishes and leads to the overproduction of oxidative sub-
stances [23, 26, 29].
It is well established that inflammatory and insulin/
IGF-1 signalling pathways interact [23, 30]. Subclinical in-
flammation, such as in obesity or related to other chronic
disease risk factors, increases insulin resistance [30–31].
Adipokine production in obesity is abnormal and some pro-
inflammatory signalling pathways are induced. The white
adipose tissue of obese persons produces pro-inflammatory
cytokines including TNF-α and IL-6 in excess, possibly
due to the infiltration by macrophages. These changes in
cytokine production by adipocytes and macrophages are
believed to contribute to obesity-related insulin resistance
[23].
The link between systemic low-grade inflammation and
insulin/IGF-1 signalling is biologically meaningful. Insulin
and IGF-1 are both potent mitogens, stimulate cell prolifer-
ation and are anti-apoptotic. By modulating their action in
response to inflammatory mediators, tissue damage can be
diminished. Inflammatory processes and resulting oxidant
radicals damage DNA, lipids and proteins. As our body is
continuously exposed to these highly reactive and electro-
philic compounds, it had to develop defence mechanisms to
prevent excessive tissue damage. Anti- and pro-inflammat-
ory cytokines therefore interact with numerous signalling
pathways that modulate the cell cycle, cell proliferation and
apoptosis. Receptors involved in the immune response trig-
ger transduction pathways that activate the phosphoryla-
tion process and transcriptional factors. Pro-inflammatory
cytokines are thereby able to alter insulin/IGF-1 signalling
[30, 32–33]. Protein kinases IKKb and JNK, as well as as-
sociated transcription factors NF-kB and AP1, are involved
in the inhibition of phosphorylation of insulin/IGF-1 sig-
nalling, respectively. Both pathways are activated in obese
subjects in response to adipokines, free fatty acids and ox-
idative stress [33].
Insulin/IGF-1 receptor signalling activates the PI3K/
Akt kinase cascade which can then either activate or inhibit
the function of several downstream pathways [34–35]. PI3/
Akt signalling through FoxO (forkhead box group O) or
NF-kB transcription factors is one of the key regulators of
survival and mitosis. It plays a central role in cell cycle ini-
tiation, stress resistance and ageing [34–36].
Evidence from genetic studies on
longevity: the link to systemic
inflammation, insulin/IGF-1 signalling
and cell cycle control
Even though longevity, ageing and susceptibility to age-re-
lated diseases are not exchangeable characteristics of hu-
man populations, approaches of systems biology to study
protein-protein interactions have identified substantial
overlaps between common signature networks of genes and
proteins associated with longevity and major age-related
diseases [8]. These common signature networks are en-
riched with signalling proteins. They point to several path-
ways of potential relevance to both longe-vity and chron-
ic diseases, such as pathways associated with cell-cell and
cell-extracellular matrix interactions, focal adhesion, and
the adherens junctions [8]. They also include the insulin/
IGF-1 signalling cascade with its tight links to adiposity
and systemic inflammation [8, 20, 27].
Results from a recent genome wide scan for longevity
determinants in the Framingham cohort [34], as well as
from several candidate gene studies [36–42], provide
strong support for the central role of insulin/IGF-1 and PI3/
Akt signalling in longevity. FoxO gene variants have been
identified as determinants of longevity in several of these
studies.
FoxO transcription factors exhibit different physiolo-
gical functions including regulation of cell cycles and
growth, apoptosis, DNA repair and resistance to oxidative
stress. They codetermine lifespan in C. elegans and Dro-
sophila [36, 43–44]. Malfunctions in FoxO genes are in-
volved in various cancers, insulin resistance, altered im-
mune responses and organ damage [36]. FoxO transcrip-
tion factors are involved in the regulation of whole body
energy metabolism and glucose homeostasis and accord-
ingly in insulin resistance [34–35, 44]. They induce the ex-
pression of several antioxidative and stress resistance genes
and have a critical role in regulating the immune system
[34–35]. Depending on the type of activation, they can ex-
ert diverse and even opposite effects [25, 45–46]. FoxO
genes are negatively regulated by the PIK3/Akt pathway.
In response to stress, specific FoxO genes may be further
silenced by the SIRT1 gene [25, 34–35]. SIRT1 is itself a
regulator of insulin/IGF-1 signalling and is known to down
regulate p53-mediated senescence via deacetylation [25,
47]. Caloric restriction leads to an increase in SIRT1 activ-
ity [48]. Both, sirtuins and FoxO genes are evolutionarily
conserved [42].
While insulin/IGF-1 signalling down-regulates the ex-
pression of FoxO transcription factors, it is known to ac-
tivate NF-kB signalling and to thereby potentiate inflam-
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matory responses, prevent autophagic clearance of cellular
waste, and inhibit apoptosis of senescent cells [34–35]. The
SIRT1 and SIRT6 longevity-related transcription factors
can repress NF-kB signalling [34–35]. Thus the NF-kB and
FoxO signalling pathways are important counter players in
ageing and senescence. Excessive insulin/IGF-1 signalling
blocks the FoxO branch of PI3/Akt signalling, and con-
versely activates the NF-kB branch [34–35].
The evidence presented above suggests that systemic
low-grade inflammation, through pathways that include in-
sulin/IGF-1 signalling, may be a key link between longev-
ity, ageing and chronic diseases, as these mechanisms are
tightly linked to the regulation of cellular and tissue fate
[25].
Air pollution: a global disease risk
factor potentiating the adverse effects
of obesity and insulin resistance?
We hypothesise that systemic low-grade inflammation, in-
sulin/IGF-1 signalling and downstream pathways including
cell cycle control may mediate the effect of other chronic
disease risk factors with inflammatory properties. The
question arises whether such risk factors may even poten-
tiate the health consequences of the obesity epidemic. This
seems of particular relevance for air pollution, which is
reaching epidemic dimensions in parallel to obesity and
urbanisation [30, 49–50]. The strong inflammatory proper-
ties of air pollutants, and especially of particulate matter
(PM), are well established [25] and may explain the mul-
tiple effects of these inhaled toxicants on different organs
and diseases including the lung, the cardiovascular system
and the brain [32, 51–54].
Considering the inflammatory properties of air pollu-
tion, and given the interaction between systemic inflamma-
tion and insulin/IGF-1 signalling, what is the evidence for
an aetiological effect of PM on insulin resistance and the
metabolic syndrome? The prevalence of these conditions is
also dramatically increasing on a global scale, in parallel to
obesity, air pollution and urbanisation [21, 30]. While evid-
ence on the inflammatory properties and effects of PM is
abundant [55–57], evidence for the association between air
pollution and the metabolic syndrome is more limited [32,
53, 54, 58, 59]. Several studies have demonstrated that type
2 diabetics are more sensitive to the PM impact on heart
rate variability [59]. Recently, Sun et al. [32] demonstrated
that ambient PM2.5 potentiated the effect of obesity on in-
sulin resistance, visceral adiposity, and inflammation in a
diet-induced murine model. Particle exposure was shown
to alter PI3K/Akt signalling in the aorta of the animals. The
data suggest that the previously observed link between PM
exposure and type 2 diabetes [53–54] may in fact be me-
diated by the exaggeration of insulin resistance and vis-
ceral inflammation due to PM. Knuckles and colleagues
[60] studied changes in the transcriptome and transcrip-
tion factor proteome of rat neonatal cardiomyocyte (RCM)
cultures following an acute exposure to bio-available con-
stituents of PM2.5 oil combustion particles. Genomic alter-
ations observed included insulin/IGF-1 and PI3/AKT sig-
nalling and suggest an impact of the particles on cardiac
myocyte electrophysiological remodelling, cellular oxidat-
ive stress and apoptosis. Diesel exhaust emissions can ac-
tivate redox-sensitive transcription factors including NF-
kB and AP1, both linked to insulin/IGF-1 signalling.
The PI3K/Akt pathway, which is in part regulated by
insulin/IGF-1 signalling as outlined above, plays a key role
in cell cycle progression, although the detailed mechanisms
are still poorly understood [61]. It is of interest to note that
cycle control emerged as one of the mechanisms being rep-
resented in several chronic diseases, following Cluett and
colleagues’ [7] review and comparison of findings from
genome-wide association studies across different age-re-
lated disorders such as cardiovascular disease, cancer, type
2 diabetes, osteoporosis and dementia. A key role of cell
cycle control is meaningful from an evolutionary perspect-
ive. Senescence seems particularly important in the protec-
tion against tumour development in an environment that
continuously exposes the human organism to oxygen-de-
rived radicals that damage DNA. However, cell cycle con-
trol genes involved in tumour biology may also be of rel-
evance to other inflammation and oxidative stress- related
diseases, as they regulate senescence and therefore tissue
remodelling beyond an impact on DNA repair [25].
Inflammation and tissue remodelling are key charac-
teristics of several chronic airway diseases. Several lines
of evidence imply altered expressions of cyclin-dependent
kinases (CDK), which are key players in cell cycle control,
in emphysema, impairment of lung function, and tissue re-
modelling in the lung [25]. PM has been found to alter the
regulation of G1 cyclins and CDKs in alveolar epithelial
cells [62]. Functional genetic variants in key cell cycle con-
trol genes, namely p21, p53 and cyclin D1, strongly modi-
fied the effect of air pollution on age-related lung function
decline [63]. The same gene variants modified the associ-
ation between oxidative stress-related factors and the risk
of breast and colorectal cancer [64–65].
The expected benefit of genetics in
chronic disease epidemiology
For clinical medicine and public health to benefit from
the recent advances in various -omics disciplines, epidemi-
ological research needs to be conducted in the context
of internationally harmonised cohorts and biobanks. Very
large sample sizes are needed for the investigation of com-
plex gene-environment interactions and the identification
of public health-relevant risk patterns. Projects such as the
UK Biobank are characterised by the collection of many
biological specimens, by the detailed lifestyle and exposure
characterisation of subjects as well as by the identification
of many different health outcomes, in many cases through
linkage with disease and death registries [66]. Large
biobanks and broad research consortia have led to the de-
tection of numerous novel genes for age-related diseases
through genome-wide association studies over the past few
years [67].
However as only modifiable, exogenous risk factors
can be the target for prevention, what then is the expected
benefit from the tremendous investments into genetics over
the past two decades? It is important to point out the differ-
ences between monogenetic and complex disorders in the
context of this question. Our thinking about the benefits
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of genetics has long been dominated by its link to mono-
genetic disorders. In genetic syndromes, the identification
of disease causing DNA variants provides opportunities for
diagnosis, reproductive counselling and sometimes drug
development. The benefit of genetics in complex diseases
is less obvious and more controversially discussed. The
dramatic increase in age-related diseases over the past dec-
ades is primarily the result from changes in lifestyle and
environment. Results from recent genome-wide association
studies show that single gene variants are associated with
age-related diseases mostly at relative risks below 1.50 [3].
Contrary to monogenetic disorders, genetic tests for age-re-
lated and complex diseases are of little to no value today
on an individual basis. Rather, genetic and other biological
markers in chronic disease epidemiology must be viewed
as research instruments helping to improve our understand-
ing of disease classification and susceptibility, biologic-
al mechanisms and causality in risk factor-disease associ-
ations [68].
The example of c-reactive protein (CRP) demonstrates
some of the benefits of genetics. CRP is a correlate of low-
grade chronic inflammation. Some evidence suggests that
CRP may actively contribute to inflammation. However, as
this evidence is inconclusive, it is still unclear whether the
association between CRP and some age-related diseases in-
cluding cancer is in fact causal [69]. The Mendelian ran-
domisation approach benefits from the fact that inherited
gene variants, contrary to blood concentrations, are stable
over a person’s lifetime and are neither influenced by dis-
ease nor by exogenous exposures. This approach was ap-
plied to explore CRP as a disease biomarker in several
studies of different diseases. Mostly, CRP gene variants
have been found to be associated with altered plasma CRP
levels, but not with disease risks, suggesting that CRP may
not have a causal role in the disease process.
In addition to the clarification of causality in exposure-
disease associations, genetics also harbours the potential to
improve understanding of susceptibilities. Few well char-
acterised gene-environment interactions exist to date.
Firstly, the effect of smoking on bladder cancer risk de-
pends on the efficiency with which N-acetyltransferase 2
(NAT2) metabolises smoking carcinogens. The NAT2 effi-
ciency is genetically determined [70]. Secondly, the effect
of genetically inherited, severe alpha-1-antitrypsin defi-
ciency on the development of COPD seems to be restricted
to subjects exposed to inhaled toxicants, mostly from cigar-
ette smoking [71]. Failure to consider genetic susceptibility
may weaken the capacity to identify modifiable risk factors
[3]. The reverse is true, too: failure to consider the lifestyle
and environment of subjects may weaken the capacity to
identify the most relevant disease genes in a specific pop-
ulation. The interaction of gene- and exogenous risk factor
networks has been largely ignored in genome-wide associ-
ation studies [72]. Yet, as statistical methods for assessing
gene-environment interactions and considering a priori in-
formation for pathway analysis are now being developed
[72–74], this will be an important next step in genetic epi-
demiology.
Conclusions
Obesity and air pollution are two globally important risk
factors for age-related diseases and overall mortality. In
both cases, the molecular and causal mechanisms mediat-
ing the adverse health effects remain poorly understood. As
a result, causality of the disease associations of different
obesity parameters and air pollution components is still a
matter of debate. With regard to air pollution regulation,
the identification of genetically and otherwise susceptible
population groups is of great importance. The Swiss laws
require legal limits for air pollutants to protect the most
susceptible members of the population (ht-
tp://www.admin.ch/ch/e/rs/c814_01.html). It is hypothes-
ised that alterations in systemic low-grade inflammation,
insulin resistance and cell cycle control may, at least in
part, underlie the adverse health effects of obesity and air
pollution. Susceptibilities to these two exposures may thus,
in part, be determined by variations in gene regulation of
these signalling pathways. To test this hypothesis, interac-
tions of obesity and air pollution with these selected gene
variants must be investigated in future studies.
The public health relevance of understanding causal ef-
fects of obesity and air pollution, as well as common un-
derlying mechanisms, is the fact that physical inactivity
and excess calorie intake are tightly linked to air pollution,
all indicators of urbanisation and globalisation of lifestyle
[75]. The genetic background of different populations may
further modify susceptibility to these risk factors. Asian
populations seem to be more sensitive to obesity and ex-
hibit higher risks for type 2 diabetes under comparable liv-
ing conditions [76]. Finally, there is evidence that the age
of exposure to western lifestyles modifies the impact of in-
sulin resistance on chronic disease risk. Some studies sug-
gest that malnutrition in utero or during early childhood is a
predisposition to adult onset diabetes [77]. Thus, as mech-
anisms underlying ageing and chronic diseases are com-
plex, research approaches must be complex, too.
Funding / potential competing
interests
No funding. No conflict of interest.
References
1 World Health Organization. 2008–2013 Action plan for the global
strategy for the prevention and control of non-communicable diseases.
WHO Press, Geneva, Switzerland 2008. http://www.who.int/nmh/pub-
lications/ncd_action_plan_en.pdf
2 Preventing chronic diseases: a vital investment - WHO global report.
Geneva: World Health Organization, 2005.
3 Khoury MJ, Wacholder S. Invited commentary – from genome-wide
association studies to genome-environment-wide interactions studies –
challenges and opportunities. Am J Epidemiol. 2009;169:227–30.
4 Fallin MD, Matteini. Genetic epidemiology in aging research. J Geron-
tol A Biol Sci Med Sci. 2009;64:47–60.
5 Ebrahim S, Davey Smith G. Mendelian randomization: can genetic
epidemiology help redress the failures of observational epidemiology?
Hum Genet. 2008;123:15–33.
6 Davies RM, Wagner EG, Groves T. Advances in managing chronic dis-
ease. BMJ. 2000;320:525–6.
Review article Swiss Med Wkly. 2010;140:w13072
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 7
7 Cluett C, Melzer D. Human genetic variations: beacons on the pathways
to successful ageing. Mech Ageing Dev. 2009;130(9):553–63.
8 Wolfson M, Budovsky A, Tacutu R, Fraifeld V. The signaling hubs at
the crossroad of longevity and age-related disease networks. Int J Bio-
chem Cell Biol. 2009;41(3):516–20.
9 Thomas A. Identifying and preventing diseases in an ageing world. Ma-
turitas. 2010;65:85–6.
10 Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of
breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62.
11 Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, et al.
Cancer linked to Alzheimer disease but not vascular dementia. Neuro-
logy. 2010;74(2):106–12.
12 Barabasi AL. Network medicine – from obesity ot the "diseasome”. N
Engl J Med. 2007;357(4):404–7.
13 Go K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The hu-
man disease network. PNAS. 2007;104(21):8685–90.
14 Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: prevalen-
ce, consequences, and causes of a growing public health problem. Am
J Med Sci. 2006;331:166–74.
15 Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-
Barbash R, et al. Overweight, obesity, and mortality in a large pro-
spective cohort of persons 50 to 71 years old. N Engl J Med.
2006;355(8):763–78.
16 De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al.
Body mass index as a predictor of fracture risk: A meta-analysis. Osteo-
poros Int. 16:1330–8.
17 Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond
WD, et al. Long-term mortality after gastric bypass surgery. N Engl J
Med. 2007;357(8):753–61.
18 Teucher B, et al. Obesity- Focus on all-cause mortality and cancer. Ma-
turitas. 2010:65:112–6.
19 Nejat EJ, et al. Predictors of chronic disease at midlife and beyond – the
health risks of obesity. Maturitas. 2010:65:106–11.
20 Fontana L. The scientific basis of caloric restriction leading to longer
life. Curr Opin Gastroenterol. 2009;25:114–50.
21 Melnik BC. Permanent impairment of insulin resistance from preg-
nancy to adulthood: the primary basic risk factor of chronic Western
diseases. Medical Hypotheses. 2009;73:670–81.
22 Loh WJ, North BV, Johnston DG, Godsland IF. Insulin resistance-re-
lated biomarker clustering and subclinical inflammation as predictors
of cancer mortality during 21.5 years of follow-up. Cancer Causes Con-
trol 2010;21:709–18.
23 Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al.
Recent advances in the relationship between obesity, inflammation, and
insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
24 Long VD, Fontana L. Calorie restriction and cancer prevention: meta-
bolic and molecular mechanisms. Trends in Pharmacological Science.
2010;31:89–98.
25 Karrasch S, Holz O, Jörres RA. Aging and induced senescence as
factors in the pathogenesis of lung emphysema. Resp Med.
2008;102:1215–30.
26 Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G,
Grimalidi MP, et al. Inflammatory networks in ageing, age-related dis-
eases and longevity. Mech Ageing Dev. 2007;128:83–91.
27 Bonafè M, Olivieri F. Genetic polymorphism in long-lived people: cues
for the presence of an insulin/IGF-pathway-dependent network affect-
ing human longevity. Mol Cell Endocrinol. 2009;299(1):118–23.
28 Fontana L. Modulating human aging and age-associated diseases.
Biochimica and Biophysica Acta. 2009;1790:1133–8.
29 Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G,
Franceschi C, et al. Innate immunity and inflammation in ageing: a
key for understanding age-related diseases. Immun Ageing.
2005;2(8):1–14.
30 Zappulla D. Environmental stress, erythrocyte dysfunctions, inflamma-
tion, and the metabolic syndrome: adaptations to CO2 increases? J Car-
diometab Syndr. 2008;3(1):30–4.
31 Dandona P, Aljada A, Bandyopadhyay. Inflammation: the link between
insulin resistance, obesity and diabetes. Trends Immunl.
2004;25(1):4–7.
32 Sun Q, Yue P, Deiuliis JA, Lumeng CN, Kampfrath T, Mikolaj MB,
et al. Ambient air pollution exaggerates adipose inflammation and in-
sulin resistance in a mouse model of diet-induced obesity. Circulation.
2009;119:538–46.
33 Antuna-Puente B, Feve B, Fellahi S, Bastard J-P. Adipokines: the
missing link between insulin resistance and obesity. Diabetes Metab.
2008;34(1):2–11.
34 Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation
via AKT/IKK/NF-kB signaling. Cellular Signalling 2009, in press.
35 Salminen A, Kaarniranta K. NF-kB Signaling in the aging process. J
Clin Immunol. 2009;29:397–405.
36 Li Y, Wang W-J, Cao H, Lu J, Wu C, Hu F-Y, et al. Genetic association
of FOXO1A and FOXO3A with longevity in Han Chinese populations.
Hum Mol Genet. 2009;18(24):4897–904.
37 Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, et al.
FOXO3A genotype is strongly associated with human longevity.Proc
Natl Acad Sci. 2008;105(37):13987–92.
38 Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein
H, Nikolaus S, et al. Association of FOXO3A variation with human
longevity confirmed in German centenarians. Proc Natl Acad Scie.
USA 2009;106:2700–5.
39 Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli
G, et al. Association of the FOXO3A locus with extreme longevity in a
southern Italian centenarian study. Rejuventation Res. 2009;12:95–104.
40 Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri
C, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) re-
ceptor and phosphoinositide 3-kinase genes affect IGF-I plamsa levels
and human longevity: cues for an evolutionarily conserved mechanism
of life span control. J Clin Endocrinol Metab. 2003;88(7):3299–304.
41 Kojima T, Kamei H, Aizu T, Arai Y, Takayama M, Nakazawa S, et
al. Association analysis between longevity in the Japanese population
and polymorphic variants of genes involved in insulin and insulin-
like growth factor I signaling pathways. Exp Gerontol.
2004;39(11-12):1595–8.
42 Kuningas M, Magi R, Westendorp RG, Slagboom PE, Remm M, van
Heemst D. Haplotypes in the human Foxo1a and Foxo3a genes; impact
on disease and mortality at old age. Eur J Hum Genet.
2007;15(3):294–301.
43 Lunetta K, D’Agostino Sr RB, Karasik D, Benjamin EJ, Guo C-Y,
Govindaraju R, et al. Genetic correlates of longevity and selected age-
related phenotypes: a genome-wide association study in the Framing-
ham Study. BMC Medical Genetics. 2007;8(Suppl 1):S13.
44 Gross DN, van den Heuvel APJ, Birnbaum MJ. The role of FoxO in the
regulation of metabolism. Oncogene. 2008;27:2320–36.
45 Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et
al. Stress-dependent regulation of FOXO transcription factors by the
SIRT1 deacetylase. Science. 2004;303:2011–5.
46 Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et
al. Mammalian SIRT1 represses forkhead transcription factors. Cell.
2004;116:551–63.
47 Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et
al. Human SIR2 deacetylases p53 and antagonizes PML/p53-induced
cellular senescence. Embo J. 2002;21:2383–96.
48 Wolf G. Calorie restriction increases life span: a molecular mechanism.
Nutr Rev. 2006;64:89–92.
49 Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al.
Air pollution and cardiovascular disease: a statement for healthcare pro-
fessionals from the Expert Panel on Population Science of the Americ-
an Heart Association. Circulation. 2004;109:2655–71.
50 Bhatnagar A. Environmental cardiology: studying mechanistic links
between pollution and heart disease. Circ Res. 2006;99:692–705.
51 Pope CA 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski
D, et al. Cardiovascular mortality and long-term exposure to particulate
air pollution: epidemiological evidence of general pathophysiological
pathways of disease. Circulation. 2004;109:71–7.
Review article Swiss Med Wkly. 2010;140:w13072
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 7
52 Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH,
Anderson GL, et al. Long-term exposure to air pollution and incidence
of cardiovascular events in women. N Engl J Med. 2007;356:447–58.
53 Brook RD, Jerret M, Brook JR, Bard RL, Finkelstein MM. The relation-
ship between diabetes mellitus and traffic-related air pollution. J Occup
Environ Med. 2008;50:32–8.
54 Chen JC, Schwartz J. Metabolic syndrome and inflammatory responses
to long-term particulate air pollutants. Environ Health Perspect.
2008;116:612–7.
55 Van Eeden SF, Ran WC, Suwa T, Mukae H, Terashima T, Fuji T, et al.
Cytokines involved in the systemic inflammatory response induced by
exposure to particulate matter air pollutants (PM10) Am J Respir Crit
Care Med. 2001;164:826–30.
56 Pope CA 3rd, Dockery DW. Health effects of fine particulate air pollu-
tion: lines that connect. J Air Waste Manag Assoc. 2006;56(6):709–42.
57 Utell MJ, Frampton MW, Zareba W, Devlin RB, Cascio WE. Cardiovas-
cular effects associated with air pollution: potential mechanisms and
methods of testing. Inhal Toxicol. 2002;14(12):1231–47.
58 O’Neill MS, Veves A, Zanobetti A, Sarnat JA, Gold DR, Economides
PA, et al. Diabetes enhances vulnerability to particulate air pollution-
associated impairment in vascular reactivity and endothelial function.
Circulation. 2005;111:2913–20.
59 O’Neill MS, Veves A, Sarnat JA, Zanobetti A, Gold DR, Economides
PA, et al. Air pollution and inflammation in type 2 diabetes: a mechan-
ism for susceptibility. Occup Environ Med. 2007;64:373–9.
60 Knuckles TL, Dreher KL. Fine oil combustion particle bioavailable
constituents induce molecular profiles of oxidative stress, altered func-
tion, and cellular injury in cardiomyocytes. J Toxicol Environ Health A.
2007;70:1824–37.
61 Liang J, Slingerland JM. Multiple roles of the PI3/PKB (Akt) pathway
in cell cycle progression. Cell Cycle. 2003;2:339–45.
62 Zhang J, Ghio AJ, Gao M, Wei K, Rosen GD, Upadhyay D. Ambient
particulate matter induces alveolar arrest: role of G1 cyclins. FEBS
Lett. 2007;581:5315–20.
63 Imboden M, Schwartz J, Schindler C, Curjuric I, Berger W, Liu SL,
et al.; SAPALDIA Team. Decreased PM10 exposure attenuates age-re-
lated lung function decline: genetic variants in p53, p21, and CCND1
modify this effect.Environ Health Perspect. 2009;117(9):1420–7.
64 Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch
N.The effect of cyclin D1 (CCND1) G870A-polymorphism on breast
cancer risk is modified by oxidative stress among Chinese women in
Singapore. Carcinogenesis. 2005;26(8):1457–64.
65 Probst-Hensch NM, Sun CL, Van Den Berg D, Ceschi M, Koh WP,
Yu MC.The effect of the cyclin D1 (CCND1) A870G polymorphism
on colorectal cancer risk is modified by glutathione-S-transferase poly-
morphisms and isothiocyanate intake in the Singapore Chinese Health
Study.Carcinogenesis. 2006;27(12):2475–82.
66 Palmer LJ. UK Biobank: bank on it. Lancet. 2007;369:1980–2.
67 Davis RL, Khoury MJ. The emergence of biobanks: practical design
considerations for large population-based studies of gene-environment
interactions. Community Genet. 2007;10:181–5.
68 Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the
bottle-will we get our wish? N Engl J Med. 2008;358(2):105–7.
69 Boffetta P. Exploring a cancer biomarker: the example of c-reactive pro-
tein. JNCI. 2010;102:142–4.
70 Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation,
GSTM1 null genotype, and risk of bladder cancer: results from the
Spanish Bladder Cancer Study and meta-analyses. Lancet.
2005;366:649–59.
71 Senn O, Russi EW, Imboden M, Probst-Hensch NM. Alpha1-antitrypsin
deficiency and lung disease: risk modification by occupational and en-
vironmental inhalants. Eur Resp J. 2005; 26:1–9.
72 Eleftherohorinou H, Wright V, Hoggart C, Hartikainen A-L, Jarvelin
M-R, Balding D, et al. Pathway analysis of GWAS provides new in-
sights into genetic susceptibility to 3 inflammatory diseases. PLoS One.
2009;4(11):e8068.
73 O’Dushlaine C, Kenny E, Heron E, Segurado R, Gill M, Morris DW,
Corvin A. The SNP ratio test: pathway analysis of genome-wide asso-
ciation datasets. Bioinformatics. 2009;25(20):2762–3.
74 Yu K, Li Q, Bergen AW, Pfeffer RM, Rosenberg P, Caporaso N, Kraft
P, Chatterjee N. Pathway analysis by adaptive combination of p-values.
Genet Epidemiol. 2009;33(8):700–9.
75 Campbell T, Campbell A. Emerging disease burdens and the poor in cit-
ies of the developing world. J Urban Health. 2007;84:154–64.
76 Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in
Asia. Asia Pac J Clin Nutr. 2008;17(Suppl 1):37–42.
77 Whincup PH, Kaye SJ, Owen CG; et al. Birth weight and risk of type 2
diabetes: a systematic review. JAMA. 2008;300(24):2886–97.
Review article Swiss Med Wkly. 2010;140:w13072
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 7 of 7
